Prednisolone Impurity 12
 
		Product Description
CAT No.
				
									ALN-P027046								
				CAS No.
				
									NA								
				Mol. F.
				
									C23H28O5								
				Mol. Wt.
				
									384.5								
				Stock
				
									Please Inquire								
				
										
							
										Product Overview
						
											
										
							
										Technical Data
						
											
										
							
										Reference
						
											
										
							
										RFQ
						
									
							
							
							Product Overview
			
						
									Chemical Name : 2-((10R,11S,13R)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate								
				
									Smiles : C[C@]12C(C3CCC4=CC(C=C[C@]4(C)C3[C@@H](O)C2)=O)=CCC1C(COC(C)=O)=O								
				
									Inchi : InChI=1S/C23H28O5/c1-13(25)28-20(12-24)18-7-6-17-16-5-4-14-10-15(26)8-9-22(14,2)21(16)19(27)11-23(17,18)3/h8-10,12,16-17,19,21,27H,4-7,11H2,1-3H3/b20-18-/t16?,17?,19-,21?,22-,23-/m0/s1								
				
							
							
							Technical Data
			
						
							
							
							Reference
			
						Validated stability indicating RP-LC assay for determination of gatifloxacin and prednisolone acetatein ophthalmic preparations and biological samples
									By Qadir, Muhammad A.; Shahzad, Shabnam; Ahmed, Mahmood; Razzaq, Syed S.; Shafiq, Muhmmad I.nFrom Latin American Journal of Pharmacy (2016), 35(5), 912-920								
				Novel stability indicating RP-HPLC method for the simultaneous estimation of moxifloxacin and prednisolone in bulk and their combined dosage form
									By Potnuri, Naga Raju; Rao, G. Devala; Prasad, Y. Rajendra – From International Journal of Pharmaceutical Sciences and Research (2015), 6(5), 1965-1973 								
				Development and validation of a new stability indicating reversed phase liquid chromatographic method for the determination of prednisolone acetate and impurities in an ophthalmic suspension
									By Marley, Adrian; Stalcup, Apryll M.; Connolly, Damian – From Journal of Pharmaceutical and Biomedical Analysis (2015), 102, 261-266								
				
							
							
							RFQ
			
						
 
                             
                             
                             
                             
                            